CR6736A - 5-alquilpirido[2,3-d[ piridinas como inhibidores de tirosina kinasa - Google Patents

5-alquilpirido[2,3-d[ piridinas como inhibidores de tirosina kinasa

Info

Publication number
CR6736A
CR6736A CR6736A CR6736A CR6736A CR 6736 A CR6736 A CR 6736A CR 6736 A CR6736 A CR 6736A CR 6736 A CR6736 A CR 6736A CR 6736 A CR6736 A CR 6736A
Authority
CR
Costa Rica
Prior art keywords
inhibitors
typosine
alquilpirido
piridines
kinasa
Prior art date
Application number
CR6736A
Other languages
English (en)
Inventor
John Booth Richard
Myra Dobrusin Ellen
Laurence Toogood Peter
Norman Vanderwel Scott
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of CR6736A publication Critical patent/CR6736A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Se refiere a compuestos utiles para el tratamiento de trastornos de la proliferacion celular como cancer, arteroclerosis, y restenosis. Estos compuestos son inhibidores potentes de kinasas dependientes de ciclina y de kinasas reguladas por factores de crecimiento.
CR6736A 2000-03-06 2002-08-23 5-alquilpirido[2,3-d[ piridinas como inhibidores de tirosina kinasa CR6736A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US18712400P 2000-03-06 2000-03-06

Publications (1)

Publication Number Publication Date
CR6736A true CR6736A (es) 2004-03-10

Family

ID=22687699

Family Applications (1)

Application Number Title Priority Date Filing Date
CR6736A CR6736A (es) 2000-03-06 2002-08-23 5-alquilpirido[2,3-d[ piridinas como inhibidores de tirosina kinasa

Country Status (37)

Country Link
EP (1) EP1268476A1 (es)
JP (1) JP2003528101A (es)
KR (1) KR20020075805A (es)
CN (1) CN1422268A (es)
AP (1) AP2002002643A0 (es)
AR (1) AR034119A1 (es)
AU (1) AU2001233028A1 (es)
BG (1) BG107161A (es)
BR (1) BR0109056A (es)
CA (1) CA2401368A1 (es)
CO (1) CO5280200A1 (es)
CR (1) CR6736A (es)
CZ (1) CZ20022929A3 (es)
DZ (1) DZ3308A1 (es)
EA (1) EA200200802A1 (es)
EE (1) EE200200506A (es)
GT (1) GT200100037A (es)
HN (1) HN2001000040A (es)
HR (1) HRP20020798A2 (es)
HU (1) HUP0300136A2 (es)
IL (1) IL151480A0 (es)
IS (1) IS6524A (es)
MA (1) MA26881A1 (es)
MX (1) MXPA02008535A (es)
NO (1) NO20024235L (es)
NZ (1) NZ520962A (es)
OA (1) OA12227A (es)
PA (1) PA8513201A1 (es)
PE (1) PE20011177A1 (es)
PL (1) PL358271A1 (es)
PY (1) PY0104899A (es)
SK (1) SK12472002A3 (es)
SV (1) SV2001000338A (es)
TN (1) TNSN01036A1 (es)
WO (1) WO2001070741A1 (es)
YU (1) YU66502A (es)
ZA (1) ZA200207110B (es)

Families Citing this family (85)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7053070B2 (en) * 2000-01-25 2006-05-30 Warner-Lambert Company Pyrido[2,3-d]pyrimidine-2,7-diamine kinase inhibitors
US7235551B2 (en) 2000-03-02 2007-06-26 Smithkline Beecham Corporation 1,5-disubstituted-3,4-dihydro-1h-pyrimido[4,5-d]pyrimidin-2-one compounds and their use in treating csbp/p38 kinase mediated diseases
CN100525768C (zh) 2000-10-23 2009-08-12 史密丝克莱恩比彻姆公司 新化合物
DE60206363T2 (de) * 2001-02-12 2006-07-06 F. Hoffmann-La Roche Ag 6-substituierte pyridopyrimidine
JP4166991B2 (ja) * 2001-02-26 2008-10-15 田辺三菱製薬株式会社 ピリドピリミジンまたはナフチリジン誘導体
US20030100572A1 (en) * 2001-06-21 2003-05-29 Ariad Pharmaceuticals,Inc. Novel pyridopyrimidones and uses thereof
WO2003000011A2 (en) * 2001-06-21 2003-01-03 Ariad Pharmaceuticals, Inc. Novel pyridopyrimidines and uses thereof
MXPA04005939A (es) 2002-01-22 2005-01-25 Warner Lambert Co 2-(piridin-2-ilamino)-pirido[2,3-d]pirimidin-7-onas.
KR20040103972A (ko) 2002-04-19 2004-12-09 스미스클라인 비참 코포레이션 신규 화합물
DE60313339T2 (de) 2002-07-31 2008-01-03 Critical Outcome Technologies, Inc. Protein tyrosin kinase inhibitoren
US7629347B2 (en) 2002-10-09 2009-12-08 Critical Outcome Technologies, Inc. Protein tyrosine kinase inhibitors
MXPA05007503A (es) * 2003-01-17 2005-09-21 Warner Lambert Co Heterociclicos 2-aminopiridina sustituidos como inhibidores de proliferacion celular.
US6861422B2 (en) 2003-02-26 2005-03-01 Boehringer Ingelheim Pharma Gmbh & Co. Kg Dihydropteridinones, processes for preparing them and their use as pharmaceutical compositions
AU2004255934B2 (en) * 2003-07-11 2010-02-25 Warner-Lambert Company Llc Isethionate salt of a selective CDK4 inhibitor
EP1663204B1 (en) * 2003-08-29 2014-05-07 Exelixis, Inc. C-kit modulators and methods of use
RU2348632C2 (ru) 2003-11-13 2009-03-10 Ф.Хоффманн-Ля Рош Аг Гидроксиалкилзамещенные пиридо-7-пиримидин-7-оны
DE102004029784A1 (de) 2004-06-21 2006-01-05 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue 2-Benzylaminodihydropteridinone, Verfahren zur deren Herstellung und deren Verwendung als Arzneimittel
DE102004033670A1 (de) 2004-07-09 2006-02-02 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Pyridodihydropyrazinone, Verfahren zu Ihrer Herstellung und Ihre Verwendung als Arzneimittel
FR2873118B1 (fr) 2004-07-15 2007-11-23 Sanofi Synthelabo Derives de pyrido-pyrimidine, leur application en therapeutique
US7759485B2 (en) 2004-08-14 2010-07-20 Boehringer Ingelheim International Gmbh Process for the manufacture of dihydropteridinones
US20060074088A1 (en) 2004-08-14 2006-04-06 Boehringer Ingelheim International Gmbh Dihydropteridinones for the treatment of cancer diseases
US20060035903A1 (en) 2004-08-14 2006-02-16 Boehringer Ingelheim International Gmbh Storage stable perfusion solution for dihydropteridinones
US7728134B2 (en) 2004-08-14 2010-06-01 Boehringer Ingelheim International Gmbh Hydrates and polymorphs of 4[[(7R)-8-cyclopentyl-7-ethyl-5,6,7,8-tetrahydro-5-methyl-6-oxo-2-pteridinyl]amino]-3-methoxy-N-(1-methyl-4-piperidinyl)-benzamide, process for their manufacture and their use as medicament
US20060058311A1 (en) 2004-08-14 2006-03-16 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation
EP1630163A1 (de) 2004-08-25 2006-03-01 Boehringer Ingelheim Pharma GmbH & Co.KG Dihydropteridinonderivative, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel
EP1786817A1 (de) * 2004-08-26 2007-05-23 Boehringer Ingelheim International GmbH Pteridinone als plk (polo like kinase) inhibitoren
DE102004058337A1 (de) 2004-12-02 2006-06-14 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung von annelierten Piperazin-2-on Derivaten
AU2006204724A1 (en) 2005-01-14 2006-07-20 Millennium Pharmaceuticals, Inc. Cinnamide and hydrocinnamide derivatives with raf-kinase inhibitory activity
US20080096905A1 (en) 2005-03-25 2008-04-24 Glaxo Group Limited Process For Preparing Pyrido[2,3-D]Pyrimidin-7-One And 3,4-Dihydropyrimido{4,5-D}Pyrimidin-2(1H)-One Derivatives
US7423042B2 (en) 2005-03-25 2008-09-09 Glaxo Group Limited Compounds
MY145343A (en) 2005-03-25 2012-01-31 Glaxo Group Ltd Novel compounds
PE20061193A1 (es) 2005-03-25 2006-12-02 Glaxo Group Ltd DERIVADOS DE 3,4-DIHIDROPIRIMIDO[4,5-d]PIRIMIDIN-2-[1H]-0NA COMO INHIBIDORES DE QUINASA p38
US7737155B2 (en) * 2005-05-17 2010-06-15 Schering Corporation Nitrogen-containing heterocyclic compounds and methods of use thereof
FR2887882B1 (fr) * 2005-07-01 2007-09-07 Sanofi Aventis Sa Derives de pyrido[2,3-d] pyrimidine, leur preparation, leur application en therapeutique
US7642270B2 (en) 2005-09-14 2010-01-05 Janssen Pharmaceutica N.V. 5-oxo-5,8-dihydro-pyrido-pyrimidine as inhibitors of c-fms kinase
TW200800983A (en) 2005-09-14 2008-01-01 Janssen Pharmaceutica Nv 5-oxo-5,8-dihydro-pyrido-pyrimidines as inhibitors of C-FMS kinase
CN102746298A (zh) * 2005-10-07 2012-10-24 埃克塞里艾克西斯公司 PI3Kα的吡啶并嘧啶酮抑制剂
EA016945B1 (ru) 2005-10-07 2012-08-30 Экселиксис, Инк. ПИРИДОПИРИМИДИНОНОВЫЕ ИНГИБИТОРЫ PI3Kα
FR2896246B1 (fr) 2006-01-13 2008-08-15 Sanofi Aventis Sa Derives de pyrido-pyrimidone, leur preparation, leur application en therapeutique.
US7439358B2 (en) 2006-02-08 2008-10-21 Boehringer Ingelheim International Gmbh Specific salt, anhydrous and crystalline form of a dihydropteridione derivative
PT2074122E (pt) 2006-09-15 2011-08-24 Pfizer Prod Inc Compostos de pirido(2,3-d)-pirimidinona e sua utilização como inibidores de pi3
WO2008047307A1 (en) * 2006-10-16 2008-04-24 Gpc Biotech Inc. Pyrido [2, 3-d] pyrimidines and their use as kinase inhibitors
EP1914234A1 (en) 2006-10-16 2008-04-23 GPC Biotech Inc. Pyrido[2,3-d]pyrimidines and their use as kinase inhibitors
WO2008055013A2 (en) * 2006-10-31 2008-05-08 Janssen Pharmaceutica N.V. 5-oxo-5,8 - dihydro - pyrido - pyrimidines as inhibitors of c-fms kinase
FR2910813B1 (fr) 2006-12-28 2009-02-06 Sanofi Aventis Sa Nouvelle utilisation therapeutique pour le traitement des leucemies
NZ580327A (en) * 2007-04-03 2012-02-24 Array Biopharma Inc IMIDAZO[1,2-a]PYRIDINE COMPOUNDS AS RECEPTOR TYROSINE KINASE INHIBITORS
JP5129812B2 (ja) * 2007-06-15 2013-01-30 Ｍｓｄ株式会社 ビシクロアニリン誘導体
WO2009019205A1 (en) 2007-08-03 2009-02-12 Boehringer Ingelheim International Gmbh Crystalline form of a dihydropteridione derivative
EA201001030A1 (ru) 2007-12-19 2011-02-28 Амген Инк. Конденсированные соединения пиридина, пиримидина и триазина в качестве ингибиторов клеточного цикла
CA2710039C (en) 2007-12-26 2018-07-03 Critical Outcome Technologies, Inc. Semicarbazones, thiosemicarbazones and related compounds and methods for treatment of cancer
EP2100894A1 (en) * 2008-03-12 2009-09-16 4Sc Ag Pyridopyrimidines used as Plk1 (polo-like kinase) inhibitors
US8389533B2 (en) 2008-04-07 2013-03-05 Amgen Inc. Gem-disubstituted and spirocyclic amino pyridines/pyrimidines as cell cycle inhibitors
EP2112150B1 (en) 2008-04-22 2013-10-16 Forma Therapeutics, Inc. Improved raf inhibitors
EP2318406B1 (en) 2008-07-17 2016-01-27 Critical Outcome Technologies, Inc. Thiosemicarbazone inhibitor compounds and cancer treatment methods
AR073524A1 (es) 2008-09-30 2010-11-10 Exelixis Inc Piridopirimidinonas inhibidores de pi3k a y m tor
TW201100441A (en) 2009-06-01 2011-01-01 Osi Pharm Inc Amino pyrimidine anticancer compounds
US8372970B2 (en) * 2009-10-09 2013-02-12 Afraxis, Inc. 8-ethyl-6-(aryl)pyrido[2,3-D]pyrimidin-7(8H)-ones for the treatment of CNS disorders
JP5797664B2 (ja) * 2009-12-18 2015-10-21 テンプル・ユニバーシティ−オブ・ザ・コモンウェルス・システム・オブ・ハイアー・エデュケイションＴｅｍｐｌｅ Ｕｎｉｖｅｒｓｉｔｙ−Ｏｆ Ｔｈｅ Ｃｏｍｍｏｎｗｅａｌｔｈ Ｓｙｓｔｅｍ Ｏｆ Ｈｉｇｈｅｒ Ｅｄｕｃａｔｉｏｎ 置換ピリド［２，３−ｄ］ピリミジン−７（８Ｈ）−オン及びそれらの治療用の使用
UY33221A (es) 2010-02-09 2011-09-30 Univ California MÉTODOS PARA TRATAR CÁNCER USANDO INHIBIDORES DE PI3K Y mTOR EN COMBINACIÓN CON INHIBIDORES DE AUTOFAGIA
EP2552915B1 (en) 2010-04-01 2017-07-19 Critical Outcome Technologies Inc. Compounds for the treatment of hiv
ES2525866T3 (es) * 2010-08-05 2014-12-30 Temple University - Of The Commonwealth System Of Higher Education 8-alquil-7-oxo-7,8-dihidropirido [2,3-d]pirimidina-6-carbonitrilos sustituidos en 2 y usos de los mismos
US8546566B2 (en) 2010-10-12 2013-10-01 Boehringer Ingelheim International Gmbh Process for manufacturing dihydropteridinones and intermediates thereof
US9358233B2 (en) 2010-11-29 2016-06-07 Boehringer Ingelheim International Gmbh Method for treating acute myeloid leukemia
EP2646448B1 (en) 2010-11-29 2017-08-30 OSI Pharmaceuticals, LLC Macrocyclic kinase inhibitors
EP2937349B1 (en) 2011-03-23 2016-12-28 Amgen Inc. Fused tricyclic dual inhibitors of cdk 4/6 and flt3
PL2710005T3 (pl) * 2011-05-17 2017-07-31 Principia Biopharma Inc. Inhibitory kinazy tyrozynowej
US9370535B2 (en) 2011-05-17 2016-06-21 Boehringer Ingelheim International Gmbh Method for treatment of advanced solid tumors
MX2014010176A (es) * 2012-02-23 2014-11-10 Abbvie Inc Inhibidores de cinasas de piridopirimidinona.
MX386473B (es) * 2013-02-21 2025-03-18 Pfizer Formas solidas de un inhibidor de cdk4/6 selectivo
EP3024464A1 (en) 2013-07-26 2016-06-01 Boehringer Ingelheim International GmbH Treatment of myelodysplastic syndrome
CN105294682B (zh) * 2014-07-26 2017-07-07 广东东阳光药业有限公司 Cdk类小分子抑制剂的化合物及其用途
US9867831B2 (en) 2014-10-01 2018-01-16 Boehringer Ingelheim International Gmbh Combination treatment of acute myeloid leukemia and myelodysplastic syndrome
CN105816437B (zh) 2016-03-29 2018-08-03 深圳市药欣生物科技有限公司 一种帕布昔利布的药物制剂及其制备方法
TWI646094B (zh) * 2016-06-01 2019-01-01 大陸商貝達藥業股份有限公司 Crystal form of inhibitory protein kinase active compound and application thereof
PT3497103T (pt) 2016-08-15 2021-06-17 Pfizer Inibidores de piridopirimidinona cdk2/4/6
KR102583737B1 (ko) * 2017-03-03 2023-09-26 오클랜드 유니서비시즈 리미티드 Fgfr 키나제 저해제 및 약학적 용도
JP2021514359A (ja) 2018-02-15 2021-06-10 ニューベイション・バイオ・インコーポレイテッドＮｕｖａｔｉｏｎ Ｂｉｏ Ｉｎｃ． キナーゼ阻害剤としての複素環式化合物
CN113166148B (zh) * 2018-12-07 2024-04-12 杭州英创医药科技有限公司 作为cdk-hdac双通路抑制剂的杂环化合物
CN112759589B (zh) * 2019-11-01 2022-04-08 暨南大学 嘧啶并吡啶酮类化合物及其应用
US11697648B2 (en) 2019-11-26 2023-07-11 Theravance Biopharma R&D Ip, Llc Fused pyrimidine pyridinone compounds as JAK inhibitors
EP4310084A4 (en) * 2021-03-08 2025-06-25 Jinan University Pyridopyrimidine-based compound and use thereof
AU2022289202B2 (en) * 2021-06-09 2025-09-25 Tyk Medicines (Zhengzhou) , Inc. Compound as cdk kinase inhibitor and use thereof
CN117720531A (zh) * 2022-09-16 2024-03-19 华东师范大学 作为rsk抑制剂的吡啶酮并嘧啶衍生物及其应用
WO2024099403A1 (zh) * 2022-11-10 2024-05-16 北京普祺医药科技股份有限公司 一种具有软药性质的硫醚类化合物、药物组合物及其用途
WO2024107730A1 (en) * 2022-11-14 2024-05-23 Onconova Therapeutics, Inc. Methods and compositions for treating cancer

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5620981A (en) * 1995-05-03 1997-04-15 Warner-Lambert Company Pyrido [2,3-D]pyrimidines for inhibiting protein tyrosine kinase mediated cellular proliferation
WO1998033798A2 (en) * 1997-02-05 1998-08-06 Warner Lambert Company Pyrido[2,3-d]pyrimidines and 4-amino-pyrimidines as inhibitors of cell proliferation
TR200003429T2 (tr) * 1998-05-26 2001-07-23 Warner-Lambert Company Hücresel çoğalma inhibitörleri olarak bisiklik pirimidinler ve bisiklik 3,4-dihidropirimidinler.

Also Published As

Publication number Publication date
EP1268476A1 (en) 2003-01-02
CN1422268A (zh) 2003-06-04
MA26881A1 (fr) 2004-12-20
HN2001000040A (es) 2001-09-06
PE20011177A1 (es) 2001-11-23
NZ520962A (en) 2003-09-26
BR0109056A (pt) 2003-06-03
SV2001000338A (es) 2001-11-30
AR034119A1 (es) 2004-02-04
HRP20020798A2 (en) 2004-02-29
SK12472002A3 (sk) 2003-04-01
PL358271A1 (pl) 2004-08-09
OA12227A (en) 2004-03-18
KR20020075805A (ko) 2002-10-05
IL151480A0 (en) 2003-04-10
PA8513201A1 (es) 2003-06-30
EE200200506A (et) 2004-02-16
HUP0300136A2 (en) 2003-05-28
NO20024235L (no) 2002-11-05
EA200200802A1 (ru) 2003-02-27
CA2401368A1 (en) 2001-09-27
ZA200207110B (en) 2003-12-04
AP2002002643A0 (en) 2002-12-31
TNSN01036A1 (en) 2005-11-10
BG107161A (bg) 2003-06-30
PY0104899A (es) 2003-11-03
IS6524A (is) 2002-08-23
CO5280200A1 (es) 2003-05-30
GT200100037A (es) 2002-03-04
AU2001233028A1 (en) 2001-10-03
JP2003528101A (ja) 2003-09-24
CZ20022929A3 (cs) 2003-02-12
DZ3308A1 (fr) 2001-09-27
WO2001070741A1 (en) 2001-09-27
NO20024235D0 (no) 2002-09-05
MXPA02008535A (es) 2002-12-13
YU66502A (sh) 2005-09-19

Similar Documents

Publication Publication Date Title
CR6736A (es) 5-alquilpirido[2,3-d[ piridinas como inhibidores de tirosina kinasa
AR030044A1 (es) Pirido (2,3-d ) pirimidin-2,7-diaminas inhibidores de quinasas
GT200300087A (es) 2-(2,6-diclorofenil)-diarilimidazoles
ECSP088145A (es) Derivados bicíclicos como inhibidores de la cinasa p38
MY141867A (en) Substituted pyrimidines useful as protein kinase inhibitors
BRPI0406809A (pt) Heterociclos substituìdos de 2-aminopiridina como inibidores da proliferação celular
CR20130506A (es) PIRROL[2,3-b]PIRIDINAS Y PIRROL[2,3-b]PIRIMIDINAS HETEROARILO SUSTITUIDAS COMO INHIBIDORES DE QUINASAS JANUS (DIVISIONAL EXP. 10065)
SV2002000572A (es) 2- (4-piridil) animo- 6- dialcoxifenil-pirido [2,3-d] pirimidin-7-onas
ECSP105201A (es) 2-(PIRIDIN-2-ILAMINO)-PIRIDO[2,3-d] PIRIMIDIN-7-ONAS
MXPA04002983A (es) Derivados de quinuclidina, procedimientos para prepararlos y sus usos como inhibidores del receptor muscar??nico m2 y/o m3.
CR9663A (es) Heterociclos de 1,4-dihidropiridina-condensados, procesos para preparar los mismos, uso y composiciones que los contienen
UY27225A1 (es) Inhibidores de la rho-quinasa
TNSN05007A1 (en) Novel thiophenylglycoside derivatives, methods for production thereof, medicaments comprising said compounds and use thereof.
HN2002000067A (es) Inhibidores de la rho - quinasa.
PT1325011E (pt) Metodos e compostos para tratamento de doencas proliferativas
GT200200190A (es) Compuestos de benzimidazol sustituido y su utilizacion en el tratamiento del cancer
WO2003039545A3 (en) Carboline derivatives as inhibitors of ikb in the treatment of multiple myeloma and others cancers
IL151692A0 (en) Polyamine analogues as cytotoxic agents
BR0309053A (pt) Compostos
CR8749A (es) Derivados de pirimidina para tratar el crecimiento celular anomalo
DE60100855D1 (de) 1,8-naphthalimid imidazo[4,5,1-de]acridone mit antitumorwirkung
DOP2006000145A (es) Derivados de pirido [20,3-d] pirimidina su preparación, aplicación en terapeútica .
EP1615897A4 (en) PYRIMIDINONE COMPOUNDS AS CALCILYTICA
UY26559A1 (es) Piridol [2,3-d] pirimidin-2,7-diaminas inhbidores de cinasas
UA81420C2 (en) Process for the preparation of substituted pyrimidines and pyrimidine derivatives as inhibitors of protein kinase

Legal Events

Date Code Title Description
FA Abandonment or withdrawal (granting procedure)